Список проголосовавших за комментарий " On The Wires<ul><li>Akari Therapeutics (<strong>AKTX</strong>) announced that it will hold a Research and Development Day on April 24, 2017 in New York. The event will be hosted by members of Akari's executive leadership team and will feature presentations from investigators and independent scientific advisors. The meeting will cover three main areas: Interim results from the ongoing phase 2 trial in paroxysmal nocturnal hemoglobinuria (PNH), results from the pre-clinical development program targeting new disease opportunities for their lead compound Coversin, focusing on its unique dual leukotriene B4 (LTB4)/C5 activity and new data on the pre-clinical pipeline, including the once-weekly subcutaneous formulation of Coversin. </li><li>Installed Building Products (<strong>IBP</strong>) announced today that the co is seeking to refinance approximately $96 million of debt outstanding under its existing Term Loan and $125 million outstanding under its existing Delayed Draw Term Loan. The co anticipates refinancing the Facilities with the proceeds of a new five-year $100 mln ABL revolving credit facility and a seven-year $300 mln Term Loan B facility.</li></ul>"